[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,699
Citations 0
Editorial
August 16, 2016

Where to Draw the Boundaries for Prenatal Carrier Screening

Author Affiliations
  • 1Division of Molecular Diagnostics and Clinical Genomics Center, UCLA Medical Center, Los Angeles, California
JAMA. 2016;316(7):717-719. doi:10.1001/jama.2016.10888

In this issue of JAMA, Haque et al1 report the results of the use of high-throughput molecular biologic techniques for prenatal carrier screening. As numerous reports in JAMA2,3 and elsewhere have illustrated, the technique is now in fairly wide use in the evaluation of patients with undiagnosed but presumably genetic disorders and in the detection of drug sensitivity and resistance mutations in malignant tumors. Initial results of these studies have yielded some surprising findings.

First Page Preview View Large
First page PDF preview
First page PDF preview
×